Basic Cilostazol Information

• INN (International Nonproprietary Name): Cilostazol is the international nonproprietary name for the active ingredient; the name also appears as シロスタゾール in Japanese sources.
• Brand Names Available In Australia: Pletal is the primary brand listed for Australia, supplied as 100 mg tablets in a bottle of 56.
• ATC Code: B01AC23, classifying cilostazol among antithrombotic agents and platelet aggregation inhibitors excluding heparin.
• Forms & Dosages: Film‑coated tablets are the marketed form, typically 100 mg and in some markets 50 mg; common pack sizes include blisters and bottles in counts such as 10, 14, 30, 56, 60 and 100.
• Manufacturers In Australia: Otsuka and Accord Healthcare are named among global suppliers with distribution into Australia; other global manufacturers include Mylan, Bluefish and EG Labo.
• Registration Status In Australia: Cilostazol is approved by the Therapeutic Goods Administration (TGA) and marketed in Australia, commonly under the brand Pletal.
• OTC / Rx Classification: Cilostazol is a prescription‑only medicine (Rx) in Australia and in the other countries listed in regulatory sources.

Latest Research Highlights

What Does Recent Research Say About Cilostazol For Leg Pain?

Randomised trials from 2020 through mid‑2024 continue to support cilostazol’s efficacy in intermittent claudication by improving both pain‑free and maximal walking distance compared with placebo.

Benefits typically begin over several weeks with maximal improvements seen by about 12 weeks of treatment.

Meta‑analyses pooling multiple trials report consistent gains in walking distance and symptom relief, though absolute effect sizes vary by trial design and baseline severity.

Australian registry analyses and pharmacoepidemiology reports mirror trial results in routine care settings, confirming modest but clinically meaningful functional gains.

These local data also emphasise tolerability issues such as headache and palpitations, and the need to consider cardiac safety in vulnerable groups.

Pharmacology research reaffirms the mechanism of action as phosphodiesterase III inhibition leading to increased intracellular cAMP with antiplatelet and vasodilator effects.

Adult dosing in trials commonly uses 100 mg twice daily; pharmacokinetic studies note metabolism via CYP3A4 and CYP2C19 with interaction potential.

Safety‑focused cohort studies up to 2024 reiterate contraindication in congestive heart failure and caution in significant hepatic impairment, consistent with regulatory advice and TGA safety communications.

Table Summaries And Trial Numbers Often Reported:

• Outcome measures: pain‑free walking distance, maximal walking distance, number needed to treat (NNT) for clinically meaningful gain.
• Adverse event signals: headache, palpitations, diarrhoea; rare serious cardiovascular events flagged in higher‑risk cohorts.

Clinical Effectiveness In Australia

How Well Does Cilostazol Work In Australian Clinical Practice?

Clinical use in Australia aligns with international evidence supporting cilostazol (Pletal 100 mg) for intermittent claudication due to peripheral arterial disease.

Hospital vascular services and primary care audits in Australia report modest but measurable increases in walking distance when cilostazol is combined with supervised exercise and smoking cessation.

Quality‑of‑life scores and claudication severity commonly improve in patients who respond to therapy.

TGA adverse event reports reflect expected class effects such as headache, palpitations and diarrhoea, with rare serious cardiovascular events prompting clinician vigilance.

Local clinicians typically review effectiveness at about 12 weeks and discontinue therapy if no benefit is observed.

Outcome Measures Defined:

• Pain‑Free Walking Distance: Distance walked before onset of claudication pain during a standardised treadmill or corridor test.
• Maximal Walking Distance: Total distance walked before being unable to continue due to pain.

Data‑Highlight: TGA Reported Adverse Drug Reactions — common reports include headache and palpitations; serious cardiac reports are rare but reviewed promptly by prescribers.

Note On PBS And Access: PBS coverage may vary and many prescribers manage access with private scripts or patient access schemes; always verify current PBS status before advising on cost.

Indications And Expanded Uses

What Is Cilostazol Approved For And When Is It Used Off‑Label?

Primary TGA‑approved indication is symptomatic intermittent claudication due to peripheral arterial disease.

In clinical practice some specialists may try cilostazol off‑label for microvascular ischaemia or as an adjunct in mixed vascular disease, but robust evidence beyond PAD is limited.

Cilostazol is not suitable for acute ischaemic events and must never be used to treat congestive heart failure.

Absolute Contraindications Include:

• Congestive heart failure of any grade.
• Severe hepatic impairment.
• Known hypersensitivity to cilostazol.
• Active bleeding and pregnancy.

Evidence Strength For Uses (Short Mapping):

• Intermittent Claudication: High evidence for symptomatic improvement when combined with exercise.
• Microvascular Ischaemia: Low evidence; considered investigational/off‑label in select cases.
• Acute Ischaemic Events/Heart‑Failure Management: No evidence; contraindicated.

Special Populations Note: Indigenous and comorbid populations require tailored risk–benefit discussions because baseline cardiovascular risk can be higher and monitoring resources vary regionally.

Consultation Advice: Check TGA and EMA labelling and consider local vascular specialist referral for complex cases.

Composition And Brand Landscape

What Does Each Tablet Contain And Which Brands Exist In Australia?

The active ingredient is cilostazol (INN) in film‑coated tablet form, commonly as 100 mg tablets; 50 mg strengths are available in some international markets.

In Australia the primary brand listed is Pletal, supplied as 100 mg tablets in a 56‑count bottle that matches a month‑plus supply for twice‑daily dosing.

Global suppliers and manufacturers include Otsuka, Accord Healthcare, Mylan, Bluefish and EG Labo, with multiple generics available in other markets.

Formulation Details:

• Form: Film‑coated tablet for oral administration.
• Storage: Store below 25°C and protect from moisture and light.

Australian Pharmacy Sellers: Popular retail pharmacy chains offering prescription fulfilment include Chemist Warehouse, Priceline and TerryWhite Chemmart, with availability subject to TGA/PBS listing and prescription requirement.

Packaging For Dosing Convenience: A 56‑count bottle aligns conveniently with twice‑daily 100 mg dosing for approximately four weeks of treatment.

Contraindications And Special Precautions

Who Should Not Take Cilostazol And What Precautions Are Required?

Absolute contraindications include congestive heart failure, known hypersensitivity, severe hepatic impairment, active pathological bleeding and pregnancy.

Relative contraindications include history of arrhythmia, ischaemic heart disease, uncontrolled hypertension, bleeding diatheses and concomitant multi‑antithrombotic therapy.

Special Australian Population Flags:

• Elderly frailty requires close monitoring for dizziness, palpitations and falls.
• Indigenous patients may need culturally safe discussion due to higher baseline cardiovascular risk.
• Remote/rural patients with limited emergency access require careful consideration of cardiac safety and monitoring plans.

Daily‑Life Advice: Avoid heavy machinery or driving if experiencing dizziness or palpitations and report these symptoms promptly to a health professional.

Monitoring Steps And TGA Reports: TGA‑reported serious adverse reactions include rare cardiovascular events; baseline ECG is recommended if cardiac risk factors are present and clinicians should monitor blood pressure and heart rate.

Reproductive Advice: Counsel women of childbearing potential on contraception while on therapy and avoid use in pregnancy as per contraindication.

Dosage Guidelines

How Is Cilostazol Dosed And What If A Dose Is Missed?

Standard adult dosing for intermittent claudication is 100 mg orally twice daily, taken at least 30 minutes before breakfast and dinner for better absorption and tolerability.

Onset of benefit is gradual and clinicians generally reassess at around 12 weeks, discontinuing if no clinically meaningful improvement is seen.

Dosing Adjustments And Special Notes:

• Children: Not recommended; safety and efficacy not established.
• Elderly: No routine initial reduction required, but monitor for increased sensitivity and drug interactions.
• Hepatic Impairment: Contraindicated in moderate to severe hepatic impairment.
• Renal Impairment: Use with caution in mild to moderate impairment; avoid in severe renal dysfunction.

Missed Dose: Take as soon as remembered unless the next dose is due, but do not double doses.

Overdose: Main features include tachycardia, hypotension or arrhythmias and urgent medical care is required for suspected overdose.

Interactions Overview

Which Medicines And Substances Interact With Cilostazol?

Cilostazol is metabolised mainly by CYP3A4 and CYP2C19, so strong inhibitors of these enzymes can increase cilostazol exposure and inducers may reduce effect.

Major interaction concerns include co‑administration with strong CYP3A4 inhibitors such as certain azole antifungals and some macrolide antibiotics.

Concomitant antiplatelet or anticoagulant therapy increases bleeding risk and requires careful monitoring and clinical judgement.

Alcohol may exacerbate vasodilatory adverse effects such as dizziness and tachycardia, and stimulants may increase palpitations, so counsel patients accordingly.

Practical Pharmacy Actions:

• Use clinical decision support and My Health Record interaction checks to identify significant drug‑drug interactions.
• Coordinate with specialists when managing polypharmacy in older Australians.

Cultural Perceptions And Patient Habits

How Do Australians View Cilostazol And What Affects Uptake?

Australian patients are often price sensitive and place strong trust in pharmacists for practical advice about medicines and PBS navigation.

Many people prefer to try lifestyle measures such as supervised exercise before or alongside pharmacotherapy for intermittent claudication.

Forums and patient groups frequently discuss combining walking programmes with medicines like cilostazol to maximise walking distance.

Rural And Remote Access: Telehealth e‑prescriptions and mail‑order pharmacy services are vital for patients away from major vascular clinics and for those who cannot travel easily.

Indigenous Health Context: Culturally safe communication and involvement of community health workers supports adherence and appropriate risk discussion.

Pharmacist Role: Community chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly act as first contact for side‑effect triage and PBS advice.

Urban Versus Rural Access Channels:

• Urban: Local specialist clinics, pharmacy pick‑up, supervised exercise programmes.
• Rural: Telehealth appointments, e‑scripts and mail delivery to support continuity of care.

Availability And Pricing Patterns

Where Can Patients Get Cilostazol And What Does It Cost?

Pletal 100 mg is available via community pharmacies in Australia and is supplied by manufacturers including Otsuka and Accord generics.

Pricing varies between private scripts at major chains and any applicable PBS subsidy if a listing applies; clinicians and pharmacists should check current PBS schedules before advising on cost.

Online pharmacies and telehealth services can supply prescriptions nationwide, and rural patients often rely on mail delivery and electronic prescriptions for access.

In Our Online Pharmacy Context: Cilostazol is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Sourcing Checklist For Pharmacists And Patients:

• Confirm prescription requirement and PBS eligibility.
• Discuss generic alternatives if available to reduce out‑of‑pocket cost.
• Provide storage advice (store below 25°C) and repeat prescription planning for remote follow‑up.

Comparable Medicines And Preferences

What Are The Alternatives To Cilostazol For Claudication?

Alternatives used in Australia include pentoxifylline and antiplatelets such as clopidogrel, plus supervised exercise therapy as a core approach.

Evidence tends to favour cilostazol over pentoxifylline for improving walking distance, while clopidogrel is used primarily for reducing atherothrombotic risk rather than direct symptom relief.

Choice Of Therapy Depends On Comorbidities And Patient Goals:

• Cilostazol: Better for symptomatic walking distance improvement but contraindicated in heart failure.
• Pentoxifylline: Alternative when cilostazol is unsuitable, with weaker evidence for walking distance gains.
• Clopidogrel/Aspirin: Used for vascular risk reduction rather than claudication symptoms.
• Supervised Exercise Therapy: High‑value non‑pharmacological intervention that pairs well with medicines when available.

Prescribing Considerations: Balance symptom relief, bleeding risk, heart‑failure exclusion and PBS access when selecting a medicine.

FAQ

1. How long until I see a benefit?

   Benefits are gradual and often appear over several weeks; clinicians usually reassess at 12 weeks to decide whether to continue.

2. Can I take cilostazol with aspirin or clopidogrel?

   They are often co‑prescribed for vascular risk, but combined therapy increases bleeding risk and requires monitoring by the prescriber.

3. Is cilostazol on the PBS?

   Check the current PBS listings before advising patients; availability and subsidy status can change and generics may be available privately.

4. Can I drive while on cilostazol?

   If dizziness or palpitations occur, avoid driving or operating heavy machinery until these effects resolve; seek pharmacist or medical advice if they persist.

Decision Tree — Continue Versus Stop At 12 Weeks:

• Improved walking distance and tolerable side effects: Continue with planned review and monitoring.
• No benefit or intolerable side effects: Discontinue and consider alternatives such as pentoxifylline or intensified exercise therapy.

Guidelines For Proper Use And Pharmacist Counselling

What Should Pharmacists Tell Patients When Starting Cilostazol?

Confirm the indication of intermittent claudication and screen for absolute contraindications such as congestive heart failure and severe hepatic impairment before supply.

Ask about current medications, specifically antithrombotics and strong CYP3A4/CYP2C19 inhibitors, and check for interactions with clinical decision support tools.

Counselling Points For Patients:

• Explain dosing: 100 mg twice daily, at least 30 minutes before breakfast and dinner.
• Set expectations: onset over weeks with review at 4 weeks for tolerability and at 12 weeks for effectiveness.
• Side‑effect advice: common effects include headache, palpitations and diarrhoea; advise when to seek urgent help for severe palpitations, syncope or bleeding.

Culturally Safe Care And Remote Follow‑Up: Use plain language for Indigenous clients, offer interpreters where needed and provide telehealth follow‑up for rural patients.

Monitoring Schedule For Pharmacy Use:

• Baseline: check blood pressure and heart rate; consider ECG if cardiac risk present.
• 4 Weeks: review tolerability and adherence.
• 12 Weeks: assess symptomatic benefit and decide on continuation.

Referral Pathways: Provide TGA product information or refer to a vascular specialist when diagnosis, comorbidities or response are unclear.

Delivery Across Australia